PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Molecular Cancer Therapeutics

PRMT5 inhibition by SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with bevacizumab in ovarian cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGuimei YangHDHuixia DouLXLiting Xue

Discussion

Loading...

Member takes

Overview

Demonstrates that SCR-6920 downregulates HIF-1α in ovarian cancer, suggesting its potential in combination therapies.

Key Points

  • The aim is to investigate the effects of SCR-6920, a PRMT5 inhibitor, on HIF-1α and its antitumor activity against ovarian cancer.
  • Characterization of SCR-6920 as a selective PRMT5 inhibitor
  • In vitro and in vivo assessment of antitumor activity
  • Analysis of HIF-1α regulation and VEGF expression through RNA sequencing
  • SCR-6920 effectively downregulates HIF-1α and reduces VEGF levels
  • The combined treatment of SCR-6920 and bevacizumab shows a synergistic antitumor effect
  • SCR-6920 enhances the efficacy of standard ovarian cancer therapies such as paclitaxel and doxorubicin

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69e9bb9e85696592c86ed28ehttps://doi.org/10.1158/1535-7163.mct-25-1105
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5142: PRMT5 inhibitor SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with Bevacizumab2026
  2. 2PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer2024 · 48 citations
  3. 3Targeting PRMT5 in cancer: Mechanistic insights and clinical progress2025
  4. 4Targeting PRMT5: Current Inhibitors and Emerging Strategies for Therapeutic Intervention2025 · 5 citations
  5. 5Abstract 4493: Comprehensive assay approaches for PRMT5 targeted drug discovery.2026